RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.A biotech presently trading at $114 usd just received a $10.8b usd B/O. How does a biotech currently trading at $1.14 usd get a B/O similar to this affluent neighborhood? The BOD seems unable to increase shareholder value.